Cases
Representative Matters: Advising life science companies on the creation
development of patent portfolios, collaborative research, licensing of technology, raising money through venture capital
other financial transactions,
enforcement of their intellectual property rights.
Advising university technology licensing offices on assessing industry interest in their technologies
the strength of intellectual property covering the same in order to direct resources towards technologies with greater commercialization potential.
Negotiating
drafting numerous option agreements, licensing agreements, sponsored research agreements, cooperative research agreements on behalf of life science companies acquiring intellectual property rights from universities
non-profit research organizations.
Providing patent invalidity, freedom to operate
non-infringement opinions
Counseling life science companies in patent interference, post-grant reviews, intellectual property enforcement,
litigation issues.
Performing due diligence investigations for private
public financings
M&A transactions.
Negotiating
drafting various transactional agreements for life science companies including manufacturing
supply agreements, licensing agreements, distribution agreements, material transfer agreements, clinical trial agreements, confidentiality agreements, consulting agreements,
various services agreements.
Representative Transactions
Financings: Mergers & Acquisitions (M&A): Represented a privately-held specialty pharmaceutical company in an acquisition by a publicly-traded NASDAQ pharmaceutical company for $125 million USD plus milestones.
Represented a privately-held biomedical cancer therapeutic company in an acquisition/asset purchase by a publicly-traded NASDAQ biotech company for $55.3 million USD.
Represented a publicly-traded NASDAQ biopharmaceutical company focused on rare pediatric
orphan diseases, in an acquisition of another publicly-traded NASDAQ biopharmaceutical company in an all-stock transaction valued at over $15 million USD, plus contingent value rights CVRs for up to an additional $6.5 million USD in subsequent payments.
Represented a private, pre-clinical medical technology company in the sale of its royalty rights to a major institutional investor for $8 million USD.
Represented a publicly-traded NASDAQ regenerative medicine company in the merger with two privately-held biotech companies to form a new publicly-traded NASDAQ regenerative medicine company.
Strategic Collaborations / Licensing: Represented a privately-held biomedical diagnostic company in a multi-year, worldwide Distribution Agreement with a Fortune 500 healthcare company.
Represented a publicly-traded NASDAQ genomics company in a Collaboration Agreement with a Fortune 500 pharmaceutical company worth over $1.5 billion USD.
Represented a privately-held biotech regenerative medicine company in an Exclusive Licensing Agreement with a Fortune 500 pharmaceutical company worth over $125 million USD, with $15 million USD upon signing.
Represented a subsidiary of a publicly-traded TYO pharmaceutical company in a Sponsored Research Agreement
an Exclusive License Agreement with an American university.
Represented a privately-held drug delivery company in an Exclusive License Agreement with a non-profit research hospital.
Represented a privately-held oncology company in a multi-year Cooperative Research
Development Agreement (CRADA) with the National Cancer Institute.
Initial Public Offerings (IPOs) / Financings: Represented a privately-held specialty pharmaceutical company in an IPO on NASDAQ for $70 million USD.
Represented the underwriters in the IPO of a privately-held molecular diagnostic company on NASDAQ for $82.5 million USD.
Represented the underwriters in the IPO of a privately-held biotechnology company on TSX for $42.4 million CDN, representing the largest Life Sciences IPO in Canada at the time.
Represented a publicly-traded NASDAQ biopharmaceutical company in a bond deal priced at $150 million USD.